Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

06 nov. 2013 06h00 HE | Source: Curis, Inc.

Curis Reports Third Quarter 2013 Financial Results and Provides CUDC-427 Development Update

-- CUDC-427 Phase 1 Trial Placed on Partial Clinical Hold by FDA -- -- Company to Host Conference Call Today at 8:30 a.m. EST -- LEXINGTON, Mass., Nov. 6, 2013 (GLOBE NEWSWIRE) -- Curis, Inc....
22 oct. 2013 08h14 HE | Source: Curis, Inc.

Curis and Debiopharm Group(TM) Announce Initiation of Phase I Dose Finding Clinical Study With a Combination of HSP90 Inhibitor Debio 0932 and Everolimus (Afinitor)(R)

LAUSANNE, Switzerland and LEXINGTON, Mass., Oct. 22, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of...
04 oct. 2013 07h00 HE | Source: Curis, Inc.

Curis Announces Initiation of a Roche-Sponsored Phase 1b/2 Study of Erivedge(R) (vismodegib) in Relapsed/Refractory AML and High Risk MDS

LEXINGTON, Mass., Oct. 4, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel drug candidates for the treatment of human cancers, today announced that...
26 sept. 2013 07h00 HE | Source: Curis, Inc.

Curis to Webcast Investor and Analyst Day in New York City

LEXINGTON, Mass., Sept. 26, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company developing novel drug candidates for the treatment of human cancers, today...
04 sept. 2013 07h00 HE | Source: Curis, Inc.

Curis to Present at Upcoming Investor Conferences

LEXINGTON, Mass., Sept. 4, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers,...
13 août 2013 07h00 HE | Source: Curis, Inc.

Curis Strengthens Leadership Team With Appointments of Jaye Viner, M.D. as Chief Medical Officer and Tania Chander, Pharm.D. as VP of Product Development

LEXINGTON, Mass., Aug. 13, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop next generation targeted drug candidates for the...
07 août 2013 07h00 HE | Source: Curis, Inc.

Curis to Present at the 2013 Wedbush Life Sciences Management Access Conference

LEXINGTON, Mass., Aug. 7, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers,...
05 août 2013 07h00 HE | Source: Curis, Inc.

Curis Reports Second Quarter 2013 Financial Results

LEXINGTON, Mass., Aug. 5, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers,...
29 juil. 2013 07h00 HE | Source: Curis, Inc.

Curis to Release Second Quarter 2013 Financial Results and Hold Conference Call on August 5, 2013

LEXINGTON, Mass., July 29, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers,...
25 juil. 2013 07h00 HE | Source: Curis, Inc.

Curis Announces Initiation of a Clinical Trial of CUDC-427 In Advanced Malignancies

LEXINGTON, Mass., July 25, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers,...

Page précédente